6533b857fe1ef96bd12b4555

RESEARCH PRODUCT

Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer.

Stefano IacobelliPasquale IncoronatoAnna RussoGiuseppe AiromaFrancesco PerroneLuigi BasilicoSergio PalmeriRosario PepeMaria GentileGiovannella PalmieriCesare GridelliSabino De PlacidoAngelo Raffaele BiancoVittorio GebbiaLuciano RausaCarlo GarufiG. Ferrante

subject

Cancer Researchmedicine.medical_specialtyLung NeoplasmsTime FactorsVindesinemedicine.medical_treatmentMitomycinPhases of clinical researchToxicologyGastroenterologyInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Lung cancerEtoposideEtoposideNeoplasm StagingPharmacologyChemotherapybusiness.industryMitomycin CRemission InductionCombination chemotherapymedicine.diseaseSurgeryRegimenOncologyLymphatic MetastasisVindesineDrug Evaluationbusinessmedicine.drug

description

A total of 72 patients with metastatic stage IV non-small-cell lung cancer (NSCLC) were treated with combination chemotherapy comprising the MEV regimen (mitomycin C, 8 mg/m2 given i. v. on day 1; etoposide, 100 mg/m2 given i.v. on days 1–3; and vindesine, 3 mg/m2 given i.v. on day 1; treatment repeated every 3 weeks). In 64 evaluable patients, the objective response rate was 37% (complete responses, 4.7%; partial responses, 32.3%). The median survival was 7.6 months for all patients. The treatment was very well tolerated. MEV proved to be an active and non-toxic regimen for the treatment of metastatic NSCLC.

yearjournalcountryeditionlanguage
1991-09-01Cancer chemotherapy and pharmacology
10.1007/bf00685698https://pubmed.ncbi.nlm.nih.gov/1655301